List of Zubsolv drug patents

Zubsolv is owned by Orexo Us Inc.

Zubsolv contains Buprenorphine Hydrochloride; Naloxone Hydrochloride.

Zubsolv has a total of 10 drug patents out of which 0 drug patents have expired.

Zubsolv was authorised for market use on 03 July, 2013.

Zubsolv is available in tablet;sublingual dosage forms.

Zubsolv can be used as sublingual or buccal administration of a pharmaceutical composition comprising buprenorphine and naloxone, sublingual administration of a pharmaceutical composition comprising buprenorphine and naloxone, use of zubsolv for treatment of opioid dependence.

The generics of Zubsolv are possible to be released after 18 September, 2032.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8658198 OREXO US INC Non-abusable pharmaceutical composition comprising opioids
Dec, 2027

(4 years from now)

US8470361 OREXO US INC Non-abusable pharmaceutical composition comprising opioids
May, 2030

(7 years from now)

US11020388 OREXO US INC Abuse-resistant pharmaceutical composition for the treatment of opioid dependence
Sep, 2032

(9 years from now)

US11020387 OREXO US INC Abuse-resistant pharmaceutical composition for the treatment of opioid dependence
Sep, 2032

(9 years from now)

US10946010 OREXO US INC Abuse-resistant pharmaceutical composition for the treatment of opioid dependence
Sep, 2032

(9 years from now)

US8940330 OREXO US INC Abuse-resistant pharmaceutical composition for the treatment of opioid dependence
Sep, 2032

(9 years from now)

US9439900 OREXO US INC Abuse-resistant pharmaceutical composition for the treatment of opioid dependence
Sep, 2032

(9 years from now)

US9259421 OREXO US INC Abuse-resistant pharmaceutical composition for the treatment of opioid dependence
Sep, 2032

(9 years from now)

US10874661 OREXO US INC Abuse-resistant pharmaceutical composition for the treatment of opioid dependence
Sep, 2032

(9 years from now)

US11433066 OREXO US INC Abuse-resistant pharmaceutical composition for the treatment of opioid dependence
Sep, 2032

(9 years from now)

Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 03 July, 2013

Treatment: Sublingual or buccal administration of a pharmaceutical composition comprising buprenorphine and naloxone; Sublingual administration of a pharmaceutical composition comprising buprenorphine and naloxone; Use of zubsolv for treatment of opioid dependence

Dosage: TABLET;SUBLINGUAL

How can I launch a generic of ZUBSOLV before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic